Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma.

Trial Profile

Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Dexamethasone; Filgrastim; Pegfilgrastim
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top